Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private Label Three-Day Yeast Infection Cream Offered By Taro

This article was originally published in The Tan Sheet

Executive Summary

Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.
Advertisement

Related Content

Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Taro Pharmaceuticals
Taro Pharmaceuticals
Schering-Plough 2% Gyne-Lotrimin 3 Cream Will Be Launched In February

Topics

Advertisement
UsernamePublicRestriction

Register

PS091130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel